{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:21:21Z","timestamp":1782926481447,"version":"3.54.5"},"reference-count":37,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1111\/jcpt.12384","type":"journal-article","created":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T04:51:54Z","timestamp":1458795114000},"page":"189-197","source":"Crossref","is-referenced-by-count":26,"title":["Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?"],"prefix":"10.1155","volume":"41","author":[{"given":"P. M.","family":"Aguiar","sequence":"first","affiliation":[{"name":"Department of Pharmacy; Faculty of Pharmaceutical Sciences; University of S\u00e3o Paulo; S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. M.","family":"Lima","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; Faculty of Pharmaceutical Sciences; University of S\u00e3o Paulo; S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Storpirtis","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; Faculty of Pharmaceutical Sciences; University of S\u00e3o Paulo; S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,3,23]]},"reference":[{"key":"10.1111\/jcpt.12384-BIB0001|jcpt12384-cit-0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"10.1111\/jcpt.12384-BIB0002|jcpt12384-cit-0002","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/11585930-000000000-00000","article-title":"The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information","volume":"29","author":"Messori","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"10.1111\/jcpt.12384-BIB0003|jcpt12384-cit-0003","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.socscimed.2015.02.003","article-title":"The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence","volume":"130","author":"Hostenkamp","year":"2015","journal-title":"Soc Sci Med"},{"key":"10.1111\/jcpt.12384-BIB0004|jcpt12384-cit-0004","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1586\/14737167.1.1.7","article-title":"Using economic evidence in reimbursement decisions for health technologies: experience of 4 countries","volume":"1","author":"Harris","year":"2001","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1111\/jcpt.12384-BIB0005|jcpt12384-cit-0005","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.ejca.2011.04.005","article-title":"Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodology","volume":"47","author":"Gaultney","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1111\/jcpt.12384-BIB0006|jcpt12384-cit-0006","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.critrevonc.2014.12.017","article-title":"Decision-analytic modeling studies: an overview for clinicians using multiple myeloma as an example","volume":"94","author":"Rochau","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1111\/jcpt.12384-BIB0007|jcpt12384-cit-0007","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) - explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"10.1111\/jcpt.12384-BIB0008|jcpt12384-cit-0008","unstructured":"National Cancer Institute NCI Thesaurus Chemotherapy Regimen Used to Treat Plasma Cell Myeloma (Code C63496) - Relationships https:\/\/ncit.nci.nih.gov\/ncitbrowser\/pages\/concept_details.jsf?dictionary=NCI_Thesaurus&version=15.12d&code=C63496&ns=NCI_Thesaurus&type=relationship&key=1853381027&b=1&n=0&vse=null"},{"key":"10.1111\/jcpt.12384-BIB0009|jcpt12384-cit-0009","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the economic evaluation of health care programmes","author":"Drummond","year":"2005","edition":"3"},{"key":"10.1111\/jcpt.12384-BIB0010|jcpt12384-cit-0010","unstructured":"Organisation for Economic Co-operation and Development National Accounts. PPPs and exchange rates http:\/\/stats.oecd.org\/Index.aspx?datasetcode=SNA_TABLE4"},{"key":"10.1111\/jcpt.12384-BIB0011|jcpt12384-cit-0011","unstructured":"US Department of Bureau of Labor Statistics CPI Inflation Calculator http:\/\/www.bls.gov\/data\/inflation_calculator.html"},{"key":"10.1111\/jcpt.12384-BIB0012|jcpt12384-cit-0012","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.jacc.2008.09.018","article-title":"Interpreting the results of cost-effectiveness studies","volume":"52","author":"Cohen","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jcpt.12384-BIB0013|jcpt12384-cit-0013","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness-the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12384-BIB0014|jcpt12384-cit-0014","first-page":"52","article-title":"Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma","volume":"17","author":"Mehta","year":"2004","journal-title":"Manag Care Interface"},{"key":"10.1111\/jcpt.12384-BIB0015|jcpt12384-cit-0015","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1600-0609.2010.01526.x","article-title":"The cost-effectiveness of bortezomib in relapsed\/refractory multiple myeloma: Swedish perspective","volume":"85","author":"Hornberger","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1111\/jcpt.12384-BIB0016|jcpt12384-cit-0016","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3111\/13696998.2011.611841","article-title":"Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib","volume":"14","author":"M\u00f6ller","year":"2011","journal-title":"J Med Econ"},{"key":"10.1111\/jcpt.12384-BIB0017|jcpt12384-cit-0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15410","article-title":"The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation","volume":"15","author":"Picot","year":"2011","journal-title":"Health Technol Assess"},{"key":"10.1111\/jcpt.12384-BIB0018|jcpt12384-cit-0018","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10198-012-0395-6","article-title":"Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales","volume":"14","author":"Brown","year":"2013","journal-title":"Eur J Health Econ"},{"key":"10.1111\/jcpt.12384-BIB0019|jcpt12384-cit-0019","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1634\/theoncologist.2011-0380","article-title":"The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment","volume":"18","author":"Garrison","year":"2013","journal-title":"Oncologist"},{"key":"10.1111\/jcpt.12384-BIB0020|jcpt12384-cit-0020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/CMAR.S43373","article-title":"Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece","volume":"5","author":"Fragoulakis","year":"2013","journal-title":"Cancer Manag Res"},{"key":"10.1111\/jcpt.12384-BIB0021|jcpt12384-cit-0021","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/ejh.12571","article-title":"A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model","volume":"96","author":"Blommestein","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1111\/jcpt.12384-BIB0022|jcpt12384-cit-0022","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12384-BIB0023|jcpt12384-cit-0023","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12384-BIB0024|jcpt12384-cit-0024","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"10.1111\/jcpt.12384-BIB0025|jcpt12384-cit-0025","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12384-BIB0026|jcpt12384-cit-0026","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12384-BIB0027|jcpt12384-cit-0027","first-page":"1159","article-title":"A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II\/III multiple myeloma; a prospective randomised phase III study","volume":"40","author":"Agthoven","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1111\/jcpt.12384-BIB0028|jcpt12384-cit-0028","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40273-014-0231-1","article-title":"A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis","volume":"33","author":"Hiligsmann","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1111\/jcpt.12384-BIB0029|jcpt12384-cit-0029","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ijnurstu.2014.06.004","article-title":"A systematic review of economic evaluations assessing interventions aimed at preventing or treating pressure ulcers","volume":"52","author":"Palfreyman","year":"2015","journal-title":"Int J Nurs Stud"},{"key":"10.1111\/jcpt.12384-BIB0030|jcpt12384-cit-0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1524-4733.2009.00663.x","article-title":"Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR drug cost task force report-part I","volume":"13","author":"Hay","year":"2010","journal-title":"Value Health"},{"key":"10.1111\/jcpt.12384-BIB0031|jcpt12384-cit-0031","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"key":"10.1111\/jcpt.12384-BIB0032|jcpt12384-cit-0032","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Health"},{"key":"10.1111\/jcpt.12384-BIB0033|jcpt12384-cit-0033","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0272989X12458348","article-title":"Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6","volume":"32","author":"Briggs","year":"2012","journal-title":"Med Decis Making"},{"key":"10.1111\/jcpt.12384-BIB0034|jcpt12384-cit-0034","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12916-015-0326-3","article-title":"A systematic review of cost-effectiveness analyses of complex wound interventions reveals optimal treatments for specific wound types","volume":"13","author":"Tricco","year":"2015","journal-title":"BMC Med"},{"key":"10.1111\/jcpt.12384-BIB0035|jcpt12384-cit-0035","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/bmj.38737.607558.80","article-title":"Bias in published cost effectiveness studies: systematic review","volume":"332","author":"Bell","year":"2006","journal-title":"BMJ"},{"key":"10.1111\/jcpt.12384-BIB0036|jcpt12384-cit-0036","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1017\/S0266462310000322","article-title":"Modeling in pharmacoeconomic studies: funding sources and outcomes","volume":"26","author":"Garattini","year":"2010","journal-title":"Int J Technol Assess in Health Care"},{"key":"10.1111\/jcpt.12384-BIB0037|jcpt12384-cit-0037","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s11912-001-0027-2","article-title":"Conflict of interest in industry-sponsored economic evaluations: real or imagined?","volume":"3","author":"Barbieri","year":"2001","journal-title":"Curr Oncol Rep"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12384","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12384","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12384\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T07:41:16Z","timestamp":1718437276000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,23]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12384","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3,23]]}}}